Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Klemm and colleagues present evidence supporting a role for the antibody diversification enzyme activation-induced deaminase (AID) in the generation of mutations associated with disease progression and drug resistance in chronic myeloid leukemia
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadel...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...
International audienceMost cancers become more dangerous by the outgrowth of malignant subclones wit...
Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Kle...
The introduction of the tyrosine kinase inhibitor (TKI), imatinib, has had a significant impact in i...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
SummaryChronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
Chronic myeloid leukemia (CML) is effectively treated by tyrosine kinase inhibitors (TKIs). Rarely, ...
Chronic myeloid leukemia (CML) is a myeloproliferative stem cell disease characterized by the expres...
In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associ...
Chronic myeloid leukemia (CML) was the first type of cancer in humans to be linked to a single, acqu...
Purpose of reviewImatinib, which was the first targeted therapy for patients with chronic myeloid le...
Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in mo...
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadel...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...
International audienceMost cancers become more dangerous by the outgrowth of malignant subclones wit...
Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Kle...
The introduction of the tyrosine kinase inhibitor (TKI), imatinib, has had a significant impact in i...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
SummaryChronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
Chronic myeloid leukemia (CML) is effectively treated by tyrosine kinase inhibitors (TKIs). Rarely, ...
Chronic myeloid leukemia (CML) is a myeloproliferative stem cell disease characterized by the expres...
In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associ...
Chronic myeloid leukemia (CML) was the first type of cancer in humans to be linked to a single, acqu...
Purpose of reviewImatinib, which was the first targeted therapy for patients with chronic myeloid le...
Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in mo...
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadel...
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BC...
International audienceMost cancers become more dangerous by the outgrowth of malignant subclones wit...
DOI
Add to ORKG